SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

________________

 

Date of Report (Date of earliest event reported):
April 24, 2003

Alpharma Inc.

 

(Exact name of registrant as specified in its charter)

Delaware
(State of other jurisdiction of incorporation)

1-8593
(Commission File Number No.)

22-2095212
(IRS Employer Identification)

 

One Executive Drive, Fort Lee, New Jersey 07024

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code

(201) 947-7774

 

Not Applicable

______________________________________________

(Former name or former address, if changed since

last report)

Item 7. Financial Statement and Exhibits

(c) Exhibits.

    1. Press release issued by Alpharma Inc. on April 24, 2003

Item 9. Regulation FD Disclosure (Results of Operations and Financial Condition under Item 12)

       In accordance with SEC Release No. 33-8216, the following information, intended to be furnished under "Item 12. Results of Operations and Financial Condition," is instead being furnished under "Item 9. Regulation FD Disclosure."

       On April 24, 2003, Alpharma Inc. issued a press release announcing its financial results for the first quarter of 2003. The press release is attached to this Form 8-K as Exhibit 99.1.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
 

ALPHARMA INC.
 

By: /s/ Matthew T. Farrell
 

Matthew T. Farrell
Executive Vice President and
Chief Financial Officer

Date: April 24, 2003